Cardiocity Ltd

Cardiocity is developing Rhymthpad technology that allows a patient to be screened for Hypertension during an existing 30 second hand placement screening for Atrial Fibrillation. The innovation is to combine the Cardio and Vascular side of the patient assessment simultaneously. It is hoped that more detailed analysis may be performed in a proactive screening session at each Primary Care Interaction. The benefit to the NHS is identifying patients with both AF and Hypertension earlier, allowing for a medication solution to be implemented, rather than waiting for a significant event to occur.